Search
for
Sort by
Research 30 of 77
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- The PDGF/PDGFR pathway as a drug target
- Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
- Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- Management of Toxicities of Targeted Therapies
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- Rapid hair depigmentation in patient treated with pazopanib
- Nilotinib-induced generalized keratosis pilaris: Report of a rare case
- Forum
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
- Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
- Erosive Pustular Dermatosis of the Scalp Due to Afatinib: A Rare Case
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Dermatologic Reactions to Targeted Therapy
- Premature Hair Graying: Underlying Contributors and Management Approaches - An Updated Literature Review